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Based on the clinical care pathway of delirium in palliative care (PC), a published analytic framework (AF) 
formulated research questions in key domains and recommended a scoping review to identify evidence gaps.   
Objectives 
To produce a literature map for key domains of the published AF: screening; prognosis and diagnosis; management 
and the health-related outcomes. 
Methods 
A standard scoping review framework was used by an interdisciplinary study team of nurse and physician delirium 
researchers, an information specialist and review methodologists to conduct the review. Knowledge user 
engagement provided context in refining nineteen AF questions. A peer reviewed search strategy identified 
citations in Medline, PsycINFO, Embase & CINAHL databases between 1980 and 2018. Two reviewers 
independently screened records for inclusion using explicit study eligibility criteria for the population, design, 
delirium diagnosis, and investigational intent.  
Results 
Of 104 studies reporting empirical data and meeting eligibility criteria, most were conducted in patients with 
cancer (73.1%) and in inpatient PC units (52%). The most frequent study design was a one or more group 
nonrandomized trial or cohort (67.3%). Evidence gaps were identified: delirium risk prediction; comparative 
effectiveness and harms of prevention, variability in delirium management across PC settings, advanced directive 
and substitute decision-maker input, and transition of care location; and estimating delirium reversibility. Future 

















Substantial evidence gaps exist, providing opportunities for future research regarding the assessment, prognosis 
and management of delirium in PC settings.  
Key words: delirium, palliative care, assessment, prognosis, management, analytic framework.  

















Delirium is a complex neurocognitive and behavioral manifestation of an underlying medical abnormality. Its 
frequent occurrence is therefore not unexpected in the context of patients with advanced life-threatening illness 
in palliative care (PC) settings. Although the terms PC and hospice care are often used interchangeably, PC is 
considered applicable anywhere in a person’s life-threatening illness trajectory, whereas hospice care has a more 
traditional association with the terminal phase of end-of-life care.
1
 Both specialists and generalists deliver PC 
across a variety of settings: inpatient PC units in acute care settings and stand-alone inpatient hospices; hospital PC 
consult teams; and community PC services.
1
 Although delirium is acknowledged as a frequent clinical problem in 
the context of PC,
2
 its poor recognition and documentation in clinical practice is a substantive concern.
3 4
 Across all 
healthcare settings, delirium is associated with high levels of mortality and morbidity, and poorer outcomes in 
general;
5 6
 it is thus a major contributor to healthcare costs.
7
  
Standardized clinical criteria, such as those of the International Classification of Diseases, tenth and 
recently released eleventh edition (ICD-10 and ICD-11), and the Diagnostic Statistical Manual of Mental Disorders, 
fifth edition (DSM-5) exist to aid clinicians in diagnosing delirium.
8-10
  The Confusion Assessment Method (CAM) is a 
briefly administered assessment tool that is widely used to screen for delirium.
11
 Although it was validated in 
relation to the earlier DSM-III-R criteria,
12
 it broadly operationalizes the current DSM-5 delirium criteria.
13
  The 
DSM-5 delirium features include the following: a disturbance of attention and awareness; short onset (hours to 
days) and fluctuation over the course of the day; an additional cognitive disturbance, such as disorientation, 
memory or language deficits, or perceptual abnormalities; the disturbances are not better explained by an evolving 
or existing dementia, or that they occur in a coma; and there is clinical evidence through history, examination or 
investigations that the disturbance is related to another general medical condition, substance intoxication (for 
example, a medication) or withdrawal, or multiple etiologic factors.
13
 On the basis of the type of psychomotor 
disturbance observed, delirium is classified as no motor subtype (normal psychomotor activity), hypo- or 
hyperactive, or a mixed subtype with both hypo- and hyperactive features.
14 15
 The hypoactive subtype is common 
in PC settings and is the most prone to go undetected.
16
 Misdiagnosis of delirium most commonly occurs as 
dementia and depression.
17-19
 Regular screening for delirium in PC settings has been advocated,
20 21















view of its characteristic fluctuations, the frequency of the hypoactive subtype, and the risk of misdiagnosis, but 
there has been very limited evaluation of the effectiveness of screening in this context.
22
 
Although advanced age, pre-existing or evolving dementia, and frailty may confer a baseline vulnerability 
or risk toward delirium in older persons in general,
2
 delirium occurring in the PC context is particularly precipitated 
by one or more acute medical events, such as organ failure, infection, and medication or metabolic effects.
23
 
Although baseline and precipitant risk factors for delirium have been identified in other care settings, there has 
been relatively limited evaluation of these in PC settings. Furthermore, findings from studies that evaluate either 
delirium risk or therapeutic interventions in settings such as postoperative or critical care may have limited 
generalizability to PC settings. Delirium generates high levels of distress for patients, their families and their 
professional caregivers in PC settings by impeding potentially precious communication and generating behavioral 
disturbances.
24
 The standard PC approach to delirium management involves symptomatic management, treatment 
of reversible precipitating factors (if consistent with the goals of care) in addition to patient and family support.
22 23 
25
 Symptomatic management may involve varying degrees of non-pharmacological and pharmacological 
intervention.
22 26
   
Most patients in PC settings experience an irreversible delirium in the last hours or days of life.
27
 Part or 
full reversal of delirium may occur prior to the terminal phase, but depends on the presence of modifiable etiologic 
factors, their investigation, and treatment. The patient’s goals of care are typically more focused on comfort in 
many PC settings, particularly in hospice care. This may limit the investigation and treatment of delirium 
precipitants, thus perhaps increasing the use of antipsychotic and other sedating medications to symptomatically 
treat delirium. If the goals of care are unclear and clinical uncertainty exists regarding the reversibility of an 
episode of delirium, there is a potential risk of adopting the extremes of either undue fatalism (missing potentially 
reversible delirium precipitants and premature use of deep pharmacological sedation to control the symptoms of 
delirium) or alternatively, taking an overly medicalized (inappropriately burdensome and non-cost-effective 
intervention) approach to delirium management.
23
 
The association of delirium with older age, dementia and comorbidity burden,
2 28
 and the projected 
population increase in the proportion of elderly person,
29















to guide all practitioners in palliative and end-of-life care to conduct effective, evidence-based interventions at all 
points along the clinical care pathway of delirium. Recognizing this need, our group organized an international 
interdisciplinary research planning meeting with a broad spectrum of leading delirium researchers and knowledge-
users in 2012 as part of an overarching program of research, entitled Studies to UNderstand Delirium In Palliative 
Care Settings (SUNDIPS).
30
 We identified key areas of potential uncertainty, controversy or clinical equipoise in the 
clinical care pathway of delirium in PC: the benefit/burden ratio for therapeutic decisions; the outcomes and 
impact of delirium; the goals of care; the use of deep pharmacological sedation to control the symptoms of 
delirium; cost-effectiveness issues; patient-reported outcomes, experiential impact of delirium and its treatment 
on family and caregivers; and limited access to certain therapeutic interventions and the potential need to 
transition to a new place of care, such as home to hospice or hospice to acute care. We subsequently constructed 
and published an analytic framework (AF) with pivotal research questions, based on the delirium care pathway in 
PC.
31
   
As a preliminary step, a comprehensive map of the scope and nature of the knowledge in the scientific 
literature and its gaps is a prerequisite to proceeding with systematic reviews and further clinical research 
studies.
31
 We conducted a scoping review of delirium in PC settings with specific aims: (1) to map the literature for 
the key domains and pivotal questions in the clinical care pathway of delirium in PC settings, as previously 
identified in our AF: screening, prognosis and diagnosis; management (including pharmacological and non-
pharmacological therapeutic interventions) in the context of the goals of care; and outcomes and impact, including 
clinical, experiential (patient, family and professional caregivers) and economic; (2) to identify the knowledge gaps 
and research priorities regarding delirium in PC settings, thus providing the potential to refine the existing research 
questions in our AF, and determine where systematic reviews are feasible and warranted prior to planning future 
clinical research studies; and (3) to consolidate our integrated knowledge user, consultative and collaborative 
process, as initiated in our SUNDIPS meeting, so as to address the specific contextual decision-making issues 
















Study team composition 
The core study team consisted of two PC physicians based in an inpatient care setting, a critical care physician, two 
post-doctoral PC nursing delirium researchers, a critical care pharmaco-epidemiologist, an information specialist, a 
systematic review methodologist, an epidemiologist and two research assistants. Collaborative author input was 
received from a psychiatrist that conducted many delirium studies in a hospice setting and PC physicians from 
across a variety of settings, including a community consult service, a hospital consult service and a university 
academic department.    
Scoping review framework 
A scoping review has been defined as “a form of knowledge synthesis that addresses an exploratory research 
question aimed at mapping key concepts, types of evidence, and gaps in research related to a defined area or field 
by systematically searching, selecting, and synthesizing existing knowledge.”
32
 Scoping reviews thus represent a 
novel approach to mapping the landscape of published literature. Following previous recommendations regarding 
scoping review methodology,
32 33
 we adopted a standard six-phase framework approach to the conduct of the 
review: (1) developing a rationale and identifying the research questions; (2) identifying relevant studies; (3) study 
selection; (4) charting the data; (5) collating, summarizing, and reporting the results; and (6) collaborative 
consultation, which partly preceded but was also an integral part of phase one and phase five of this framework. 
Developing a rationale and identifying the research questions 
The background and rationale for this scoping review have been described in relation to the inaugural SUNDIPS 
meeting.
30 31
 Many of the knowledge users, methods experts and independent researchers who attended this 
meeting collaborated on many of its related publications.
21 27 31 34-36
 Although a broader consultative meeting is not 
a formal requirement in scoping reviews,
33
 we considered the initial and sustained engagement of knowledge 
users (administrators, senior nursing personnel and policy developers) as an important aspect of the review. We 
therefore scheduled an initial 2-hour meeting of knowledge users and core study team members to review the 
research questions from the AF.  Through this meeting and both subsequent consultation and iterative input, the 















updated version of the AF is depicted in Figure 1 and the refined research questions, now totalling 19 are outlined 
in Table 1. We did not publish or register the protocol due to the absence of such formal arrangements for scoping 
reviews, but signalled the basis of the scoping review in our published AF paper.
31
  
Consistent with standard recommendations that the primary research question of a scoping review be 
broad, we asked the question: what is the scope and nature of the scientific literature addressing the assessment, 
management, outcomes and impact of delirium in PC settings? This broad question encompasses the specific AF 
research questions, as initially identified in the SUNDIPS meeting and further refined through subsequent 
consultation.  
Identifying relevant studies 
A search strategy was developed by an experienced information specialist (LS), and externally peer reviewed by 
another information specialist. The search was conducted across Medline (via Ovid), Embase (via Ovid), CINAHL 
(via EBSCOHost) and PsycINFO (via Ovid) databases. Pilot screening of a sample of retrieved records was employed 
to further refine the search concept and strategy and help finalize key data extraction items. The search strategy 
included a combination of various terms in relation to ‘palliative care’ and ‘delirium’. (Appendix 1, Supplementary 
Table 1) The strategy was modified as appropriate in accordance with the specific database searched. Secondary 
searching of the included studies was also used to identify and map studies in relation to the pivotal areas in the 
AF. The literature search was initially limited to the time period of 1980 to July 2
nd
 2015; further updated searches 
were conducted to December 31
st
 2016 and May 16
th
 2018. The rationale for the 1980 limit was based on the 
absence of DSM diagnostic criteria for delirium prior to 1980.  
Study selection 
The titles and abstracts of those studies identified in the literature search were uploaded into DistillerSR,
37
 a 
software program designed to support the conduct of systematic reviews. Explicit a priori eligibility criteria (Table 
2) were applied at Level 1 (title and abstract) and Level 2 (full text) screening. The principal inclusion criterion was 















from a feasibility perspective, we reserved the option of modifying the scoping review and limiting it to a subset of 
questions if either the volume of retrieved records or included studies became unmanageable.  
In addition to including relevant studies that were clearly documented as having been conducted in 
palliative settings and involving participants with a clearly defined principal palliative indicator diagnosis, we also 
included relevant studies whose study populations had cancer or Adult Immune Deficiency Syndrome (AIDS) as a 
progressive life-threatening illness and were unequivocally eligible for PC referral but had study assessments 
conducted by oncology, psychiatry, psycho-oncology or a designated supportive care service. We excluded 
publications such as editorials, commentaries, narrative reviews and letters that did not report primary empirical 
data. Studies were excluded if the diagnosis of delirium was not clearly defined according to standard criteria such 
as DSM or ICD diagnostic criteria, or a diagnostic cut-off score on a validated assessment (diagnostic or screening) 
tool such as the Confusion Assessment Method (CAM), or standard psychiatric assessment. The scoping 
methodology supported an inclusive approach, which involved the inclusion of conference abstracts and 
systematic reviews, based on their meeting eligibility criteria and their potential to address at least one of the 19 
AF questions. 
Full texts of included studies were examined to confirm inclusion, extract relevant data and map them to 
specific research questions. In the absence of a full text publication, an abstract-only article was included if it 
otherwise met the eligibility criteria. Dual screening at Levels 1 and 2 was conducted independently by two senior 
researchers (PGL and SHB) and all conflicting selections were discussed and resolved, if necessary through the 
input of a third reviewer (MTA). The single best reason for exclusion at Level 2 was also recorded. The data 
extraction process was undertaken by a single reviewer (PGL) with a two-reviewer (PGL and SHB) consensus 
reserved for unclear records. As a quality check to verify the accuracy of data extraction, a random 10% of the data 
were independently verified by a third reviewer (NAR).  
Charting the data 
Data extraction included the following items: study design; country of origin; study population; sample size; 















were tagged by the research question(s) that they addressed. In keeping with the standards for scoping reviews, 
included studies were not formally appraised for risk of bias.
33 38
 We adopted an inclusive approach to comparative 
effectiveness and harms evaluation: in addition to therapeutic interventions, we also included screening, 
diagnostic and prognostic tool evaluations if they reported some comparative effectiveness or harms outcomes. 
Collating, summarizing, and reporting the results 
Cognizant of the potential overlap between some primary studies and included systematic reviews, relevant 
findings were reported separately or discretely (for example, using the term ‘multiple’ in relation to systematic 
review characteristics) where possible to avoid exaggerating the available evidence in relation to our research 
questions.  We used the broad qualitative characteristics and the numerical distribution of mapped evidence 
addressing each of the a priori research questions to formulate our recommendations for future research: a 
subsequent systematic review, a survey of patient experience or experience of those who care for patients at risk 
of or in delirium in a PC setting, or a primary experimental/observational study to fill the knowledge gaps 
identified.  
  Towards the end of the project, once the data were summarized, the knowledge users were again 
consulted and their opinions noted in relation to future research priorities from among the research questions, the 
identified knowledge gaps and the potential for knowledge synthesis, as generated through the scoping review. 
The main outcome of our scoping review was to answer the broad primary research question and thus advance the 
SUNDIPS program of research by setting the foundation for future studies.  
Results 
Study screening and inclusion 
The literature search, including updates, identified 6800 citation records. The flow of information in identifying, 
screening and selecting studies is summarized in the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA)
39
 flow diagram in Figure 2. Screening at title and abstract level identified 390 citation records as 















the three most frequent single reasons for exclusion were the investigational intent of the study (n=90), the study 
design (n=63) and the lack of valid diagnostic criteria used for delirium diagnosis (n=56), together accounting for 
209 (73%) of the single reasons for exclusion.  A total of 104 studies therefore met the eligibility criteria for final 
inclusion.
40-143
 These included a published PhD thesis
50
 and also a prospective study with 19 patients
106
 that despite 
the arbitrary eligibility cut-off of 20 for sample size, was deemed by consensus to warrant inclusion because of the 
very few studies that prospectively evaluated terminal delirium. Eleven of the included studies were conference 
abstracts with no available full text but were included because their abstracts met the review’s eligibility 
criteria.
40,58,74,79,89,99,104,114,115,116,143
   
General study characteristics 
The general study characteristics of the included studies are summarized individually in Appendix 2, 
Supplementary Table 2, and an aggregate summary of their characteristics with citations is presented in Table 3. 
Thirty-seven studies (35.6%) originated from the USA, 14 (13.5%) from Japan, 10 (9.6%) from Canada, 6 (5.8%) 
from ≥ 2 countries, 6 (5.8%) from Australia, 5 (4.8%) from UK, 4 (3.8%) from each of Ireland, Spain and Portugal, 2 
(1.9%) from each of Netherlands, Germany, Italy and Taiwan, and 1 (1%) from each of Hong Kong, South Korea, 
Belgium, Norway, Turkey and Mexico.  
Seventy-six (73.1%) of study samples were individually comprised mostly (≥ 79%) of subjects with a cancer 
diagnosis. Eight (7.7%) studies had sample subjects with a heterogeneous mix of life-threatening diagnoses. In 3 
(2.9%) studies,
54,75,141
 all or ≥ 90% of the sample had a diagnosis of AIDS. One (1%) study was conducted exclusively 
in patients with hepatic failure
139
 and 1 (1%) exclusively in patients with dementia.
121
 In 12 (11.5%) studies, the 
palliative indicator diagnosis was unclear or not reported.  The baseline dementia status was unclear or 
unreported in 55 (52.9%) of the included studies. Patients with dementia were excluded in 15 (14.4%) studies and 
33 (31.7%) studies included or reported a mix of patients with and without dementia. In 1 (1%) study,
121
 all 
patients had dementia. Three studies reported a subgroup analysis on the basis of dementia status.
47,56,111
 One 

















Forty-eight (46.2%) studies were conducted exclusively in single centre inpatient PC units. The other PC 
specific settings of study samples consisted of a mix across hospital and community settings. Seventeen (16.3%) 
studies were conducted through a psychiatry service in an eligible population for study inclusion in our review. A 
further 15 (14.4%) studies were conducted in hospitalized oncology patients who met our population eligibility 
criteria but PC service involvement was not reported, and similarly, 1 (1%) study of patients with cancer attending 
a cancer centre emergency department was also included.  
Of the included studies, 60 (57.7%) were uncontrolled, nonrandomized trials or single group cohort 
studies, 10 (9.6%) involved two or multiple groups in a nonrandomized trial or cohort study (comparative studies 
of ≥ 2 interventions, tests, risk factors or other exposures). Forty-two (40.4%) of the included studies had either a 
prospective cohort design or a prospective cohort component, and a further 12 (11.5%) were reported as 
secondary analyses of prospectively collected data; the remainder (n=15) of the cohort studies were retrospective. 
The second most frequent design was cross-sectional, occurring in 18 (17.3%) studies. There were both 5 (4.8%) 
formal systematic reviews and randomized controlled trials among the included studies. Based on reviewer 
consensus, two additional reviews were included:
124,131
 both involved systematic literature searches and addressed 
some of the AF questions but lacked a quality appraisal of their included studies, and by definition were not formal 
systematic reviews.  Apart from these reviews, the remaining 97 included primary studies were conducted in a 
total of 25,690 subjects. Most (79.8%, n=83) of the study samples had a mix of adult age groups and were not age 
selected. Similarly, most (71.2%, n=74) of the study samples were comprised of a heterogeneous mix of male and 
female subjects. Age and sex status were either unclear or unreported in 15 (14.4%) and 25 (24%) studies, 
respectively. 
The diagnostic criteria and/or validated assessment tools used to make the diagnosis of delirium are 
summarized in Appendix 3, Supplementary Table 3.
8 9 12 55 67 82 144-156
 The most common criteria used among the 




 was used in 45 (43.3%) studies and the 
DSM-III-R
145
 in 9 (8.7%). Of validated tools, the CAM,
12




















based on psychomotor status was reported in 36 (35%) studies; one of these also reported a syndromal and 
subsyndromal classification.
127  
Studies of epidemiological burden, prediction and prevention of delirium 
Studies investigating the epidemiological burden (prevalence or incidence), prediction of and prevention of 
delirium are summarized in Table 4 in relation to related questions (Q1-Q5) from the AF. A total of 48 (46.2%) and 
31 (29.8%) studies investigated prevalence and incidence, respectively. Thirty-eight studies (36.5%) investigated 
risk factors for the onset of delirium; these included 9 (8.7%) that reported some form of risk prediction model. 
There were 2 (1.9%) studies that reported the comparative effectiveness/harms of delirium prevention 
strategies,
57,77
 one involved hydration as a preventive intervention,
57
 and no study examined delirium preventative 
management strategies guided by risk prediction. 
Studies of screening, diagnosis and classification of delirium 
Studies investigating the screening, diagnosis and classification of delirium are summarized in Table 5 in relation to 
related questions (Q6-Q9) from the AF. A total of 18 (17.3%) studies investigated delirium screening; these 
included 7 (6.7%) and 5 (4.8%) studies that investigated the diagnostic performance of a screening test against a 
reference standard, and the diagnostic performance of two or more screening tests against a reference standard, 
respectively. Nine (8.7%) studies reported the comparative effectiveness or harms of screening tests. 
 A total of 9 (8.7%) studies investigated the diagnosis of delirium; these included 6 (5.8%) and 2 (1.9%) 
studies that evaluated the test performance of a diagnostic test against a reference standard, and the test 
performance of two or more diagnostic tests against a reference standard, respectively. Three (2.9%) studies 
reported on the comparative effectiveness or harms of diagnostic tests. 
 A total of 3 (2.9%) studies investigated the psychomotor classification of delirium; these included 2 (1.9%) 
and 1 (1%) studies that investigated the diagnostic performance of a psychomotor classification test against a 
reference standard, and the diagnostic performance of two or more psychomotor classification tests against a 
reference standard, respectively. None of these studies reported on the comparative effectiveness or harms of 















Studies of the management of delirium and prediction of response 
Studies investigating the management of delirium and the prediction of response to management are summarized 
in Table 6 in relation to related questions (Q10-Q19) from the AF. A total 24 (23.1%) studies investigated the 
comparative effectiveness or harms of one or more pharmacological management approach (Q13), whereas 2 
(1.9%) studies, including a systematic review, investigated the comparative effectiveness or harms of non-
pharmacological management approaches (Q14). A total of 13 (12.5%) studies investigated risk factors for the 
prediction of response (reversibility) to the management of delirium (Q16); these included 4 (3.8%) studies of 
predictive models for reversibility (Q17). None of the included studies investigated variability in delirium 
management across PC settings (Q10, Q11), delirium management strategies incorporating advanced directives 
(Q12), or the impact of transition of care setting for delirium management (Q15). 
Reported comparative effectiveness or harms outcomes 
A total of 37 (35.9%) of the included studies reported comparative effectiveness or harms outcomes; three of 
these studies involved the use of additional assessment tools that were not previously referenced in the review: 
the Richmond Agitation-Sedation Scale (RASS),
157
 the Chinese version of the DRS (DRS-Chinese),
158
 and Mini-
mental State Examination (MMSE).
159
 (Appendix 4, Supplementary Table 4) Thirteen (12.5%) of these studies 
involved a direct comparison of 2 or more active study interventions.
46-48,54,59,62,74,80,86,94,95,103,124 
Among these there 
were 2 formal systematic reviews, one of screening tools,
62,95,119
 and one of pharmacological intervention
95
 that 
overlapped with a primary study
54
; one systematic literature review study of pharmacological interventions,
124
 
overlapping with two primary studies;
47,54 
one study of screening;
80
 the remaining 10 studies involved 
pharmacological comparisons with most having delirium severity change and adverse events related to therapy as 
study outcomes. A further 13 (12.5%) studies included two formal systematic reviews, one of screening tools
62
 and 
one of assisted hydration and delirium severity;
95
 a systematic literature review study that reported on 
effectiveness and harms of pharmacological interventions and exercise,
131
 overlapping with one primary study in 
relation to exercise;
138
 primary studies comparing one or more active study interventions against placebo
41,57
 or no 
active intervention
122,138 
or current standard management,
72,77,113,121,127
 or reference standard in the context of an 
assessment tool.
101 















after analysis; these included one systematic literature review study,
124
 overlapping with a primary study on 
olanzapine;
56
 four studies of assessment tools,
44,89,126,128
 and the remaining nine studies involved  pharmacological 
intervention.
45,53,56,69,75,85,107,117,133 
 Although a wide variety of outcomes were reported in association with 
comparative effectiveness and harms analyses, neither falls nor economic cost were among these outcomes. 
Objective outcomes were most commonly reported, for example, delirium severity measure changes and adverse 
events related to treatment were reported in 21 (20.3%) and 18 (17.3%) of studies, respectively, whereas 
experiential outcomes were infrequently reported. 
Evidence gaps and potential opportunities for further studies 
Based on identified gaps, the study group’s recommendations regarding future primary studies and related 
outcomes, endorsed by knowledge user consultation, are summarized along with systematic review opportunities 
in Table 7. Among the studies investigating the epidemiological burden (prevalence or incidence), prediction of 
and prevention of delirium (Q1-5 in AF), there were substantive study numbers to address Q1-3, with most of the 
risk factor studies reporting crude, unadjusted risk association. However, none of the studies with risk prediction 
models reported external validation (Q4) and there were only 2 studies addressing Q5, the prevention of delirium 
in PC settings. Overall, these data suggest that there are enough studies to consider systematic reviews for Q1-3 
and that further primary studies are needed for Q4-5. Among the studies investigating delirium screening (Q6-7), 
diagnosis (Q8-9), psychomotor classification (Q8 only), and management (Q13-14 and Q16-17 only) there appears 
to be sufficient numbers of studies to support the conduct of a systematic review in relation to each of these 
questions. Remarkably, none of the primary studies that were included in this scoping review addressed the 
questions regarding variability of practice across different PC settings (Q10-12), nor did any address the 
comparative effectiveness or harms of care location transition in relation to delirium (Q15), the external validation 
of any of the predictive models for delirium reversibility (Q18) or their comparative effectiveness or harms (Q19), 
















Using recommended scoping review methods, 104 published studies with empirical data were mapped onto 
research domains and key questions from a prespecified AF. In addition to the contribution of recognized delirium 
researchers, the generation of key questions and their subsequent refinement and expansion was based on the 
initial and ongoing engagement of a broad spectrum of decision makers and knowledge users from clinical, 
administrative and policy sectors in palliative and hospice care. These collective perspectives informed 
commentary on core aspects of the review: general appraisal of the literature; the strengths, challenges and 
limitations of the review; methodological and other considerations regarding future research. The emerging 
methodological concerns, as identified in the scoping review, along with related recommendations are 
summarized in Table 8.  
General appraisal of the literature 
Of the 278 excluded studies at full text level review, 56 (19.5%) were excluded because of failure to report clear or 
valid delirium diagnostic criteria, which highlights the importance of using standardized diagnostic criteria in future 
studies. Most (73.1%) of the included studies in the review were conducted in patients with cancer. This raises 
concerns for the generalizability for some research findings to the broader current and projected PC population, 
which will not only include a substantive proportion of patients with cancer but increasingly is likely to be 
comprised of a heterogeneous mix of palliative indicator diagnoses, co-morbid chronic illness and multimorbidity, 
including dementia and various organ failure diagnoses.
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 Moreover, dementia is one of the strongest risk 
factors for delirium in the elderly, yet its baseline status was either not reported or unclear in 52.9% of the studies 
included in the review. Similarly, the baseline Parkinson’s disease status was only documented in 1 study; this is a 
concern, particularly in studies of antipsychotics in delirium management and the need to determine 
extrapyramidal effects due to these medications. Of the included studies, approximately half were conducted in 
inpatient PC units, whereas only 6.7% and 2% were conducted in hospital PC consult service settings and 
community PC settings, respectively. The generalizability of any study findings across these different study settings 
could be problematic. There were few systematic reviews and randomized controlled trials (RCTs); the lack of RCTs 
may reflect ethical, symptom burden and attritional challenges of conducting such studies in frail PC populations.
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number of hospital consultation and community-based PC service studies, the deficits in baseline documentation, 
the relative paucity of RCTs and systematic reviews highlight gaps and raise both generalizability and quality 
concerns in the current literature, with the caveat that a full quality and risk of bias appraisal is beyond the remit 
of a scoping review.  
Strengths, challenges and limitations of the review 
This review has many strengths: a rigorous peer reviewed search strategy; an updated search of the most relevant 
databases; engagement of knowledge-users; interprofessional study team input with high-level clinical and 
methodological expertise; refined and expanded key questions derived from an AF that was based on the clinical 
pathway of delirium in PC; independent dual screening of records; and conduct of the review in accordance with 
recommended standards. The restriction of studies selected to those of English language is a limitation. We also 
encountered many challenges in conducting the review, some of which might also be acknowledged as limitations. 
One of the challenges encountered was semantic ambiguity in relation to delirium terminology. The 
literature on delirium is replete with multiple terms for delirium,
28
 such as encephalopathy and acute confusional 
state, to name just two. We addressed this issue in part by setting clear eligibility criteria for study inclusion: for 
the diagnosis of delirium, included studies were required to have met DSM or ICD diagnostic criteria or have used a 
diagnostic score on an assessment tool that had been either directly or indirectly validated against the DSM or ICD 
diagnostic criteria. Despite this, there were many studies of hepatic encephalopathy, for example, in which we 
strongly suspect that the subjects had delirium. However, while the criteria used specifically for hepatic 
encephalopathy were clearly met in these studies, they were not directly congruent with DSM or ICD criteria. This 
mismatch in taxonomy between the disciplines of hepatology and psychiatry meant that many of the hepatic 
encephalopathy studies were excluded at Level 1 or 2 screening phases.  
We encountered somewhat similar issues in relation to defining the PC population for the purposes of the 
review. The World Health Organization definition of PC is inclusive of those with “life-threatening illness.”
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 This 
broad definition includes many patients who are admitted to critical care units, although such units might not be 















critical care over the past decade, and although this has contributed greatly to our understanding of delirium, the 
focus and intensity of medical management may differ quite a bit between an inpatient hospice and critical care 
setting. Consequently, studies of patients admitted to critical or intensive care were excluded in our review: the 
consensus was that ultimately the inclusion of critical care studies of delirium, although desirable, might limit the 
generalizability of the scoping review findings. We acknowledge this as a limitation that was arguably unavoidable. 
We also encountered some uncertainty regarding studies of patients with cancer or AIDS as a progressive life-
threatening illness and were not necessarily seen by a PC service in consultation, yet were unequivocally eligible 
for PC referral but assessed by oncology, psychiatry, psycho-oncology or supportive care services; such studies 
were included in our review if they otherwise met the eligibility criteria. 
Although the AF key questions encompassed many of the pertinent decision-making questions in the 
clinical care pathway of delirium, we acknowledge that the review’s calibration towards addressing these clinical 
and epidemiological questions with empirical data and the consequent exclusion of grey literature and qualitative 
studies could mean that important components of care such as family education and support may have fallen 
outside the scope of the review. Similarly, by limiting the scope of screening and diagnostic assessment tools to the 
palliative care context, perhaps the search did not capture studies addressing the use of delirium assessment tools 
in other populations or contexts that might have potential applicability in the palliative care setting. Moreover, the 
outcomes reported in the included studies were largely clinical and limited in relation to patient, family and 
professional caregiver experience. Although we adopted a standardized approach to capturing data in relation to 
knowledge user input through the SUNDIPS meeting, funding restrictions meant that subsequent knowledge user 
input was recorded in a less formal, standardized and therefore transparent manner. Furthermore, lack of a more 
formal engagement of knowledge users at the end of the study can be viewed as a missed opportunity in terms of 
knowledge translation.  
Methodological and other considerations regarding future research  
Based on absence of data, primary studies are required in relation to many issues in the care pathway of delirium 
in PC settings: external validation of delirium risk prediction models; comparative effectiveness and harms of 















outcomes across the various PC settings and in relation to advanced directive and substitute decision-maker input; 
the experiential impact of transition of care location in relation to delirium management; and external validation of 
predictive models in estimating delirium reversibility. In addition to these primary study requirements, other 
primary studies and methodological issues warrant consideration.  
Our group are currently conducting systematic reviews of delirium in the palliative care context with 
regard to its epidemiological burden, assessment and reversibility. Although systematic reviews appear feasible in 
relation to some of our research questions, our preliminary concerns, based on a broad and admittedly not an in-
depth appraisal of quality and risk of bias of the selected extant literature, also indicate a need for more rigorous 
primary studies in relation to the domains or questions for which data already exists. This is particularly relevant to 
the evidence base for delirium management in PC, especially the pharmacological approach to the symptomatic 
management of delirium in PC settings, for which four RCTs were identified in the review.
41,54,94,103
 One of these 
RCTs included a placebo arm and demonstrated better symptom distress scores in the placebo treated group 
compared to the antipsychotic treated (haloperidol or risperidone) groups.
41
 This result has generated vigorous 
debate and calls for more studies regarding this issue.
164
 A recent survey of medical specialists in Palliative 
Medicine highlighted the marked variability in pharmacological management of delirious symptoms and the 
perceived need for more rigorous studies.
165
 Although RCTs contribute the highest level of evidence, depending on 
the intervention, pragmatic clinical trials, despite their challenges,
166
 may provide useful data regarding 
effectiveness, and in the PC setting may offer a more feasible alternative.   
Risk prediction models or scores for the onset and reversibility of delirium could potentially provide key 
information for optimal management decision-making by categorising and triaging patients into specific risk 
categories and accordingly tailoring patient management.
167 168
 Use of this approach has the potential to reduce 
unnecessary testing and treatment, thus minimizing related harms and costs. Evidence for risk prediction is ideally 
developed sequentially, involving development, validation and impact assessment phases.
169
 Studies of risk factors 
inform the development of high performing risk prediction models, which are subsequently externally validated in 
various relevant population subgroups and settings. Finally, evidence of their effectiveness and impact establishes 















studies exist that have established the effectiveness of an externally validated risk prediction model, while few 
extant risk prediction model development studies for delirium occurrence and reversibility were identified. Future 
research agenda filling this research gap could employ existing administrative databases to develop and validate 
rigorous risk prediction models; their clinical effectiveness could be established in subsequent studies. The degree 
to which existing databases can be examined might be compromised due to uncertainty regarding the validity of 




In terms of the various study outcomes associated with delirium management, and the recognized 
economic cost associated with delirium in other settings, we were unable to find any studies that reported an 
economic cost associated with delirium and its management in PC settings. Although delirium has a reported 
reversibility of 50% for episodes in an acute PC unit,
100
 and vigorous pursuit of reversal is often appropriate, it is 
also the case in clinical practice that delirium reversal is often inappropriately pursued with potentially 
burdensome and expensive investigations in the absence of externally validated predictive models or risk scores to 
guide the most appropriate level of therapeutic intervention. There is therefore a need to link an economic 
evaluation of delirium management with the intensity of the therapeutic attempts at delirium reversal. Some 
researchers have already begun to work towards developing a common core set of predefined delirium outcomes, 
albeit that some outcomes will be setting specific.
171
 Future primary studies will require broad collaborative input 
with substantive interdisciplinary involvement and for larger, adequately powered trials, multicentre collaboration 
is essential. Furthermore, mixed methods approaches that capture the experiences of patients and families and 
engage knowledge-users to inform and define the most meaningful outcomes in rigorously designed controlled 





In examining the scope and nature of the published scientific literature that addresses the assessment, 















existing gaps: lack of external validation of delirium risk prediction models; lack of reports on the comparative 
effectiveness and harms of prevention strategies and psychomotor classification of delirium; no data on the degree 
of variability in delirium management and related outcomes across the various types of PC settings, advanced 
directive and substitute decision-maker input, the experiential impact of transition of care location in relation to 
delirium management; and lack of external validation of predictive models in estimating delirium reversibility. 
Based on the number of studies, it appears feasible to conduct systematic reviews in relation to some aspects: the 
epidemiological burden (incidence and prevalence) of delirium, the risk factors for and diagnosis of delirium, the 
test performance of delirium psychomotor classification strategies, the pharmacological and non-pharmacological 
management of delirium, and the prediction of delirium reversibility. The scoping review’s broad appraisal of study 
quality and limited external validity of some studies, based on population selection, together raised some 
preliminary concerns that warrant a more in-depth analysis and also reflect the importance of rigor in future 
studies. In addition, future studies will require broad collaboration from a multicentre, interdisciplinary and 
administrative knowledge user perspective. Mixed methods approaches incorporating experiential outcomes for 
patient, family and professional caregivers will be required to address some of the more complex aspects of 
delirium.  
This scoping review’s findings will hopefully guide researchers and assist us towards the long-term goal of 
studies in the SUNDIPS research program: to generate knowledge synthesis and translation, inform guidelines and 
policy for delirium management and thus improve the experience of patients (and their families) with or at risk of 
delirium in PC settings and across the spectrum of end-of-life care. 
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Table 1 Research domains and questions related to analytic framework in Figure 1 
Epidemiological burden of delirium 
1. What are the incidence and prevalence rates of delirium in the various palliative care settings (acute 
care, inpatient hospice and hospital care, and community palliative services)? 
Delirium Prediction and prevention 
2. What are the baseline and precipitating risk factors for onset of delirium?  
3. What is the performance of the various delirium risk prediction models under current standards of 
care and how do they compare with each other? 
4. Does the model have transportability or external validity?    
5. What are the comparative effectiveness and harms of the various delirium-preventative 
management strategies (including but not limited to management guided by delirium risk 
prediction) among themselves or between them and a no delirium-preventative management 
option? 
Screening for Delirium in PC settings 
6. What is the test performance of the various delirium screening tests (e.g. cognitive active screening, 
informal caregiver observational passive screening, etc.) and how do they compare with each other? 
7. What are the comparative effectiveness and harms of the various delirium screening tests/strategies 
among themselves or between them and a no screening option (e.g. cognitive active screening of all 
patients versus cognitive active screening triaged by nurse/informal caregiver observational passive 
screening for important delirium associated outcomes)? 
Diagnosis and classification of Delirium 
8. What is the diagnostic performance of the various validated delirium diagnostic and classification 
tools (in current use) and how do they compare with each other?     
9. What are the comparative effectiveness and harms of the various validated delirium diagnostic and 
classification tools/strategies (in current use) among themselves or between them and a no 
diagnostic testing option or no classification option, respectively? 













10. What is the extent of variability in management of delirium across the various care settings (acute 
care, inpatient hospice and hospital care, and community palliative services)?   
11. Is the variability in management of delirium across the various care settings (acute care, inpatient 
hospice and hospital care, and community palliative services) associated with important differences 
in outcomes of benefits and harms?  
12. What are the comparative effectiveness and harms of delirium management strategies that 
incorporate advanced directives and/or substitute decision maker input versus those that do not?   
13. What are the comparative effectiveness and harms of the various pharmacologic symptom directed 
interventions among themselves, against non-pharmacologic therapies or a no therapy option?  
14. What are the comparative effectiveness and harms of the various nonpharmacologic symptom 
directed interventions among themselves, against pharmacologic therapies or a no therapy option?  
15. For patients in community settings (private home, nursing home, long-term care facility) who 
develop delirium in the context of predominantly palliative goals of care, what is the comparative 
effectiveness (e.g. higher probability of reversal of delirium; quality of life gain; reduction of family 
caregiver burden) and harms (undue invasive procedures, break in continuity of care, burdensome 
transition; potential separation from family) of transfer to hospital care settings (emergency or 
inpatient care) or inpatient hospice care for subsequent management versus continued care in their 
community settings? What patient or environmental factors might explain any observed 
heterogeneity in outcomes across studies? 
Prediction of response to management and treatment of Delirium  
16. In patients with established delirium, what are the risk factors that predict its non-reversibility or its 
complete or partial reversibility and sustainability of response?  
17. What is the performance of the various risk prediction models that predict complete or partial 
reversibility of delirium under current standards of care and how do they compare with each other? 
18. Does the model have transportability or external validity?    
19. What are the comparative effectiveness and harms of patient management guided by models 
predicting delirium reversibility among themselves or between them and a no delirium prediction-














Table 2 Eligibility criteria for delirium scoping review 
1. Inclusion criteria: a record was included if it provided an answer to at least one of the 19 questions 
(see Table 1) in the analytic framework (see Figure 1) and meets none of the exclusion criteria. 
2. Exclusion criteria: a record was excluded if it met one or more of the criteria (a-i); reviewers selected 
a single best response. 
a) Availability: insufficient information to ascertain relevance beyond title (neither abstract nor full 
text are available) 
b) Language: abstract and/or full text of record is in a language other than English  
c) Sample size: less than 20 participants  
d) Population: not adult (exclusively or as an analytic subgroup) or does not meet the contextual 
criterion of patients in palliative care settings (admitted to an inpatient palliative care or hospice 
unit; followed by a hospital consult palliative care team; having cancer or AIDS as a progressive 
life-threatening illness and unequivocally eligible for palliative care referral but assessed by an 
oncology, psychiatry, psycho-oncology or supportive care service;  or under the care of a 
community hospice or palliative care program) 
e) Diagnosis of delirium: is not clearly defined according to standard criteria such as one or more of 
the following: Diagnostic and Statistical Manual (DSM) of Mental Disorders criteria for delirium, 
International Classification of Diseases (ICD) diagnostic criteria, a diagnostic cut-off score on a 
validated assessment (diagnostic or screening) tool such as the Confusion Assessment Method 
(CAM), or standard psychiatric assessment 
f) Design: it is not a systematic review, randomized controlled trial or analytic observational study 
(cohort, case-cohort, nested case-control, case-control or time series)  
g) Investigational intent (primary or secondary): does not aim to empirically investigate any of the 
following:  
• incidence or prevalence estimates of delirium or its level of reversal (complete, partial or non-
reversal) 
• risk factors for delirium onset or its reversal (complete, partial or non-reversal) 
• accuracy, performance, effectiveness or harms of medical tests for screening, diagnosis or 













• development, performance, validation, effectiveness or harms of risk prediction models for 
delirium onset or its reversal (complete, partial or non-reversal) 
• comparative effectiveness or harms of delirium-preventative management strategies   
• variability in management of delirium across palliative care settings 
• comparative effectiveness or harms of delirium management or treatment, transfer to hospital 
care settings (emergency or inpatient care) or inpatient hospice care for subsequent management 
• cost-effectiveness of delirium screening, diagnosis, classification, prognosis, or 
management/treatment 
h) Insufficient information: investigational intent, study design, population, or sample size remains 
unclear due to insufficient information in full text or abstract only records     













Table 3 Aggregate summary of study characteristics of included studies (N=104) 
Study characteristics Studies 
N=104 (%) 






















Palliative indicator diagnosis*  
Cancer in all or ≥ 90% 
40,42,43,45-53,55-57,60,61,63-66,68-73,77-81,83,85-88,90-94,96-108,111-118,122,125,127,129-133,135-138,140 
74 (71.2) 


















Care setting or service  





























Inpatient PCU with community PC setting
120
 1 (1) 
Other specific PC settings  11 (10.6) 






Hospital PC outpatient setting
104
  1 (1) 
Multiple PC settings in formal systematic reviews and systematic literature reviews
62,90,91,95,124,131 
6 (5.8) 






Cancer center emergency department
70 
1 (1) 











Mixed prospective cohort and cross-sectional parts
135 
1 (1) 

















 2 (1.9) 
Non-formal systematic review study with systematic literature review†
124,131
 2 (1.9) 







































Unclear or reported 
40,43,44,47,58,65,67,74,79,80,82,89,90,95,102,104,114-116,119,121,124,131,139,143
 25 (24) 
*In 2 additional studies,
102,136
 cancer was the principal palliative indicator diagnosis in 87.2% and 79% of subjects, 
respectively. 
†Both of these reviews involved systema@c literature searches and addressed some of the AF ques@ons but lacked 













Table 4 Studies that addressed the epidemiological burden, prediction and prevention of 
delirium 
Research domains and related 
questions (Q)†  
Study Reference Number Studies 
N=104 (%) 
Epidemiological burden of Delirium 








Prediction and Prevention 
Q 2 Investigates risk factor(s) for 







Q 3  Involved development of 
delirium risk prediction 
model (or score)  
73,81,83,105,114,119,134,141,142 9 (8.7) 
Q 4 Investigates transportability 
or external validity of risk 
prediction model 
 0 (0) 
Q 5 Investigates effectiveness 
and/or harms of delirium- 
preventative management 
strategies guided by risk 
prediction 
 0 (0) 
Compares effectiveness and 
harms of other delirium-
preventative management 
strategies with each other 
or routine care? 



























Table 5 Studies that addressed screening, diagnosis and classification of delirium 
Research domains and related questions (Q)†  Study reference numbers Studies 
N=104 (%) 
Screening  
Q 6 Investigates screening to detect 






Investigates the diagnostic performance 
of a delirium screening test vs a reference 




Investigates the comparative diagnostic 
performance of delirium screening tests 
(Test A vs reference standard; Test B vs 




Q 7 Investigates comparative effectiveness 
and/or harms of screening tests among 





Diagnosis and Classification  





Investigates the diagnostic performance 





Investigates the comparative diagnostic 
performance of delirium diagnostic tests 
(Test A vs reference standard; Test B vs 
same reference standard) 
82,110 2 (1.9) 
Q 9 Investigates comparative effectiveness 
and/or harms of diagnostic tests among 
themselves or between them and routine 














Q 8  Investigates diagnostic performance of 1 
or more psychomotor classification 
test(s) of delirium 
84,109,131 3 (2.9) 
Q 9 Investigates comparative 
effectiveness/harms of 1 or more 
psychomotor classification test(s) of 
delirium 
 0 (0) 













Table 6 Studies that addressed the management of delirium and prediction of response 
Research domains and related quesons (Q)†  Study reference numbers Studies 
N=104 (%) 
Management approach 
Q 13  Investigates comparative 
effectiveness and/or harms of ≥ 1 
pharmacological management 





Q 14 Investigates comparative 
effectiveness and/or harms of ≥ 1 
non-pharmacological 
management approach to 
delirium  
131,138 2 (1.9) 
Prediction of response to management 
Q 16  Prediction of response 






Q 17 Investigates model development 
for predictors of delirium 
reversibility 
98,100,102,111 4 (3.8) 
†Domains and questions (Q10-Q19) from the analytic framework as presented in Table 1 and Figure 1: 














Table 7 Future research recommendations regarding delirium in palliative care settings 
Research strategy AF domain/questions (Qs)  Relevant focus or recommendation 
Systematic review (SR)  Epidemiological burden (Q1) • Incidence and prevalence; pooled estimates 
Prognosis (Q2-3) • Predictive model and risk association studies 
Screening (Q6) • Screening test performance and CEH 
Diagnosis (Q8-9) • Diagnostic test performance and CEH 
Classification (Q8) • Sufficient studies for test performance only 
Management (Q13-14) and 
reversibility (Q16-17) 
• CEH; current formal SRs require updating  
• Predictive model and risk association studies 
Primary studies  Risk factor identification and 
prevention strategies 
(Q2-5) 
• Predictive models for delirium occurrence; 
predictive score to determine risk; CEH of such 
models/scores 
•  RCTs of preventive strategies, particularly non-
pharmacological interventions to prevent 
delirium 
Screening, diagnosis and 
classification (Q6-9) 
• Diagnostic performance studies of assessment 
tools in these domains  
• CEH studies of screening, diagnosis and 
psychomotor classification 
Management issues (Q10-19) • Variability across PC settings and related 
outcomes 
• Advanced directives and goals of care 
designation 
• Community studies and impact of transition of 













• Pharmacological and particularly non-
pharmacological intervention; both RCTs and PTs 
• Externally validated predictive models for 
reversibility 
Outcomes needing further 
evaluation (related to Q2-19 in 
AF) 
• CEH in general, including assessment and 
management interventions 
• Experiential (patient/family/professional 
caregiver) 
• Economic cost 
AF: analytic framework; CEH: comparative effectiveness or harms; RCT: randomized controlled trial; PC: palliative 














Table 8 Additional methodological considerations regarding future research 
Methodological issue Recommendation 
Defining a palliative care 
population 
• Reality is that the PC population is becoming increasingly heterogeneous; 
some studies (eg, risk factor evaluation) may benefit from selecting a more 
homogeneous sample regarding palliative indicator diagnosis; alternatively, 
consider stratification or subgroup analysis  
Delirium diagnosis • Use ICD/DSM standard criteria or standard cut-off score on a tool validated 
against ICD/DSM criteria  
• Diagnostic algorithm for chart diagnosis/coding in database studies 
Baseline documentation of 
dementia status 
• Document due to potential impact on outcomes and their evaluation; 
consider stratification or subgroup analysis on the basis of dementia status 
Baseline documentation of 
Parkinson’s disease status 
• Document particularly in studies of antipsychotics; potential to cause 
extrapyramidal side-effects 
Outcomes: definition; 
evaluation of additional 
outcomes 
• Definition of core outcomes 
• Experiential outcomes for patients, families and professional caregivers; 
mixed methods approach will likely be required for some aspects 
Collaboration • Consider multi-centre collaboration to facilitate recruitment for RCTs and 
PTs 
• Consider interdisciplinary and knowledge user collaboration 
PC: palliative care; ICD: International Classification of Disease;
9,10
 DSM: Diagnostic Statistical Manual of Mental 
Disorders
8
 RCT: randomized controlled trial; PT: pragmatic trial; 
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